Patrick G Enright Jazz Pharmaceuticals PLC (JAZZ) insider trading activity

Patrick G Enright is Director of Jazz Pharmaceuticals plc. Currently has a direct ownership of 21,379 shares of JAZZ, which is worth approximately $3.02 Million. The most recent transaction as insider was on Aug 18, 2025, when has been sold 5,000 shares (Ordinary Shares) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 21.4K

0% 3M change

13.36% 12M change

Total Value Held $3.02 Million

PATRICK G ENRIGHT Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 18 2025	SELL Other acquisition or disposition	-	5,000 Reduced 18.95%	21,379 Ordinary Shares
Aug 08 2025	SELL Payment of exercise price or tax liability	$200,806 $111.25 p/Share	1,805 Reduced 6.4%	26,379 Ordinary Shares
Aug 07 2025	BUY Grant, award, or other acquisition	-	3,507 Added 11.07%	28,184 Ordinary Shares
Aug 02 2024	BUY Grant, award, or other acquisition	-	3,731 Added 13.13%	24,677 Ordinary Shares
Aug 14 2023	SELL Open market or private sale	$171,456 $138.16 p/Share	1,241 Reduced 5.59%	20,946 Ordinary Shares
Aug 11 2023	BUY Grant, award, or other acquisition	-	3,075 Added 12.17%	22,187 Ordinary Shares
Nov 22 2022	SELL Open market or private sale	$743,811 $149.54 p/Share	4,974 Reduced 20.65%	19,112 Ordinary Shares

Aug 08 2022	SELL Open market or private sale	$165,887 $152.33 p/Share	1,089 Reduced 4.33%	24,086 Ordinary Shares
Aug 05 2022	BUY Grant, award, or other acquisition	-	2,561 Added 9.23%	25,175 Ordinary Shares
Jul 29 2021	BUY Grant, award, or other acquisition	-	2,246 Added 9.03%	22,614 Ordinary Shares
Nov 12 2020	SELL Open market or private sale	$1,457,676 $146.81 p/Share	9,929 Reduced 32.77%	20,368 Ordinary Shares
Nov 02 2020	BUY Exercise of conversion of derivative security	-	9,929 Added 24.68%	30,297 Ordinary Shares

Also insider at

APTX

Aptinyx Inc. Healthcare

VERA

Vera Therapeutics, Inc. Healthcare

ZBIO

Zenas BioPharma, Inc.

BIOA

BioAge Labs, Inc.

PGE